Adaptive Phage Therapeutics (APT) is hiring a Curator/Bioinformatician

Adaptive Phage Therapeutics (APT) is hiring a Curator/Bioinformatician! APT is a group of seasoned veterans coupled with crazy smart biologists and engineers working to solve the problem of antibiotic-resistant infections. Each day is different and at the end of the day, you’ve made a difference in someone’s life. It’s incredibly powerful when you meet somebody whose life you impacted by going to work. The work will challenge you and reward you professionally and personally. Apply here!


In 2003, as multi-drug resistant (MDR) bacteria was starting to pose a serious international health risk, National Institutes of Health (NIH) scientist Carl R. Merril, MD, published a pivotal article that outlined prior limitations of phage therapy and suggested concepts that have emerged as the modern approach.

In 2010, the Biological Defense Research Directorate (BDRD) of the US Navy began an initiative to explore Dr. Merril’s concepts as a potential way to deal with biodefense threats associated with MDR superbugs.

In 2016 this approach achieved a significant milestone with the successful rescue of Tom Patterson, a critically ill A. baumannii infected patient. Tom Patterson’s case was immediately followed by numerous additional patient cases. In response for the need to translate the Navy’s phage research into a commercially available therapy, Adaptive Phage Therapeutics (APT) was founded by Dr. Merril and his son, Greg Merril. The company acquired world-wide exclusive rights to BDRD’s phage technology and began efforts to optimize precision phage therapy for rapid, cost effective, clinical adoption.

APT today

Today, APT is a clinical-stage biotech advancing therapies to treat multi-drug resistant infections. Prior approaches in antimicrobials have been ‘fixed’ while the pathogens continue to evolve resistance – therefore all have either become obsolete or are becoming obsolete due to antimicrobial resistance. APT’s PhageBank approach leverages an ever-expanding library of phages that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank therapy is matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. 

PhageBank is positioned to be the first antimicrobial to increase in spectrum of coverage and does not require market-suppressing antibiotic stewardship. Advanced development of APT’s therapeutics are funded in part by the US Dept of Defense.

Post a Comment

Previous Post Next Post